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Background: Despite high levels of naturally-acquired immunity (NAI) within local communities in malaria high 
transmission settings in Africa, such people often experience clinical disease during peak transmission months due to 
high parasite challenge. Major recruiters of unskilled labour in high-transmission malaria settings in Africa generally 
withhold chemoprophylactic medication from this large component of their labour force, which if administered dur-
ing peak “malaria season” could reduce incidence of clinical malaria without unduly affecting NAI.
Commentary: Naturally acquired immunity confers protection against severe clinical disease and death, but does 
not prevent mild clinical disease and, therefore, still results in worker absence and worker debilitation. Evidence exists 
that NAI persists despite periodic parasite clearance and therefore provides opportunity for drug prophylaxis during 
peak transmission months, which contributes to broader malaria elimination objectives, community well-being, and 
reduced absence from work. Such chemoprophylaxis could be by way of standard daily or weekly supervised admin-
istration of prophylactics during peak transmission months, or occasional intermittent preventive treatment (IPT), all 
aimed at reducing parasite burden and clinical disease. However, challenges exist regarding compliance with drug 
regimens over extended periods and high parasite resistance to recommended IPT drugs over much of Africa. Despite 
withholding chemoprophylactics, most large companies nevertheless pursue social responsibility programmes for 
malaria reduction by way of vigorous indoor residual spraying and bed net provision.
Conclusions: The lack of clear understanding regarding functioning of NAI and its role in malaria elimination 
campaigns, concerns about drug resistance and appropriate drug choice, lack of studies in the use of IPT in people 
other than pregnant women and small children, plus lack of guidance regarding drug options for IPT in the face of 
widespread resistance to sulfadoxine–pyrimethamine, means that large contractors in malaria endemic settings will 
likely continue to withhold malaria prophylactic drugs from locally-recruited workers, with adverse consequences on 
workforce well-being. Nevertheless, if the point of chemoprophylaxis is to reduce clinical malaria by way of reducing 
parasite challenge without significantly impacting NAI, then a comparable result can be achieved by implementation 
of effective vector reduction programmes which minimize parasite transmission but maintain NAI.
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Background
Mining and other large, labour-intensive companies 
operating in remote areas of Africa often employ hun-
dreds of local rural residents for unskilled labour. Medi-
cal staff at such facilities routinely make available or 
recommend malarial prophylactics to expatriate staff, but 
withhold it from local employees, which form the bulk of 
their establishment. This is not done for cost-saving rea-
sons, but more usually as a precautionary measure out 
of concern for disrupting naturally-acquired immunity 
(NAI) among local people, particularly against the lethal 
and most common parasite Plasmodium falciparum; 
doubts about compliance with drug-taking regimens 
among workers is also a major factor in withholding such 
malaria prophylactic drugs. NAI does not prevent clinical 
malaria, but reduces the frequency and severity of such 
events [1]. However, the consequence of withholding 
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malarial prophylactics is that the overwhelming major-
ity of malaria cases annually recorded by such mining or 
similar operations occur within the segment of locally 
employed people. This in turn gives rise to concern 
among managers not just over lost production time, but 
also because they are confronted with questions why a 
relatively high percentage of staff contract malaria, which 
is a preventable disease.
Naturally acquired immunity is a complex phenom-
enon which is still not fully understood [1–3]. Never-
theless, as a general pattern, it is well-established that 
within populations living in holo- or hyperendemic 
areas of stable malaria transmission where parasite chal-
lenge occurs regularly, NAI develops to provide vary-
ing levels of protection from severe malarial disease and 
death. This is dependent on age and frequency of infec-
tion. Infants steadily lose maternally-acquired resistance 
to clinical disease by about 6  months of age, and from 
then are susceptible to severe malaria and high risk of 
death until acquiring self-induced resistance somewhere 
between age 2 and 5. Small children in areas of high 
parasite transmission develop resistance sooner than in 
areas of less intense transmission. By puberty, children 
experiencing heavy and largely uninterrupted exposure 
to infective mosquito bites rarely develop severe disease, 
although mild clinical episodes may still be common 
[1]. This state of resistance to severe disease and death 
by malaria is then more or less maintained throughout 
adulthood although pregnant women show susceptibility 
to severe clinical malaria and death—hence intermittent 
preventive treatment (IPT) routinely provided to preg-
nant women visiting health facilities [4]. NAI generally 
is also species-specific and even strain-specific, another 
reason why regular exposure to parasites is required to 
develop and maintain broad-spectrum immunity [1, 5]. It 
is important to note that NAI does not mean complete 
absence of Plasmodium parasites in the blood, but rather 
a state of sub-clinical asymptomatic disease with low per-
sistence of parasites in the blood, in effect producing a 
constant immunological challenge and thereby maintain-
ing NAI.
Commentary
Telephonic interviews were conducted with medical 
representatives of six large international mining and 
construction operations in high transmission malaria set-
tings in eight African countries (Table 1). Without excep-
tion, all indicated that they offered malaria prophylactics 
to non-immune (generally expatriate) staff, but as a rule 
such prophylactics are not offered to locally-recruited 
employees. Aside from general concerns about interfer-
ing with naturally acquired immunity, the single most 
frequent reason given for withholding prophylactics 
is the high level of poor compliance among workers in 
taking such drugs according to prescribed schedule (no 
attempt was made to enquire on what basis such conclu-
sions were arrived at, whether by direct historic experi-
ence of the particular company or extrapolating from the 
experience of other companies, or mere assumption). 
Nevertheless, the primary motivating drive for withhold-
ing prophylactic drugs is a perception that the incidence 
of clinical malaria among workers would increase, and 
that withholding prophylactic medication from locally-
recruited workers is therefore medically justified. The 
consequence of course, is that such a policy promotes the 
widespread presence of asymptomatic carriers of malaria 
parasites within the local community and encourages the 
formation of infective gametocyte stages within many 
such asymptomatic carriers, which infect mosquitoes and 
perpetuates the malaria cycle. At broader community 
level, therefore, NAI has the overall effect of sustaining 
malaria, despite the development of some transmission-
blocking immunity reducing the efficiency of sexual stage 
gametocyte transmission to mosquitoes [6].
The concerns of mining and similar major operations 
in malarious areas of Africa regarding the use of malaria 
prophylactics, and the unintended encouragement of 
community parasitaemia as a consequence, does not 
occur in a vacuum. Broader national and international 
interests are aimed at eradicating malaria and much suc-
cess has been achieved in reducing malaria case numbers 
over the preceding decade [7]. The three predominant 
tools used in this globally coordinated campaign are 
provision of insecticide-treated bed nets (ITN’s), indoor 
residual spraying (IRS) of insecticides, and detection and 
treatment of infected persons using artemisinin-based 
combination therapy (ACT). The consequence of such 
national and international malaria control campaigns 
in theory works directly against the interests of main-
taining NAI, firstly because ITN’s and IRS dramatically 
reduce the number of malaria-transmitting mosquitoes 
and therefore reduce exposure to parasites, and secondly 
because ACT clears malaria parasites in the blood and, 
therefore, also reduces exposure to parasites. In large 
areas of Africa where stable malaria transmission is the 
norm, regular exposure to malaria parasites is required 
to maintain NAI for optimum population well-being due 
to the effect of NAI in greatly reducing malaria mortality 
and morbidity [1].
The contradictions and complexities now become 
apparent. If people spending their lives in areas of high 
malaria transmission have NAI which provides them 
safety from severe clinical malaria and death, should the 
world then stop what might be misguided humanitar-
ian efforts in eliminating malaria? Of course not. The 
most obvious reason is the very high fatality rate among 
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children below 5  years of age as a direct consequence 
of malaria—despite the ameliorating effects of NAI—
and also the debilitating impact of even mild malaria in 
subsequent years on child schooling plus the dispropor-
tionate impact on women by way of negatively affecting 
capacity for family care, income-generating activities and 
subsistence food production.
The apparent contradiction of countries engaging in 
malaria control and thereby potentially reducing NAI 
is probably not as counterproductive as may seem. Low 
levels of circulating parasites appear to be sufficient to 
maintain NAI and even periodic short-term clearance 
of infections is not necessarily bad [1, 8]; such lower lev-
els of parasite challenge may benefit a person by reduc-
ing the number of clinical malaria episodes while still 
maintaining NAI [1]. Also, the estimated half-life of NAI 
leading to reduced susceptibility to clinical malaria is 
suggested to be in the order of about 5 years, while anti-
parasite immunity that lowers parasitaemia has a half-life 
of approximately 20 years or even more [9]. This would 
explain why miners recruited in high-transmission south-
ern African states can work at malaria-free South African 
mines for most of the year and return home for annual 
vacation without apparent increase in susceptibility to 
severe malaria or death back home. It also explains why 
IPT for pregnant women is perfectly acceptable, despite 
periodic complete clearance of parasites from the blood.
Further complicating the matter is the issue of eth-
ics. However well-intentioned, a unilateral decision by 
any large international company to selectively prescribe 
healthcare within its workforce—especially when the 
decision is largely based on imperfect evidence and leads 
to one segment of workers being consciously allowed to 
contract disease—can expose that company to accusa-
tions of unfair discrimination. Clearly the issue is com-
plex, but society demands resolution of even complicated 
situations with solutions that are equitable and not open 
to hints of benevolent patronage. That is the purpose of 
this paper, to explore ways in which such companies can 
fulfil their social responsibility in a fair and even-handed 
way.
One avenue for defensible compromise that addresses 
company concerns yet addresses societal expectations 
is to offer informed choice. Locally-employed workers 
could be given appropriate presentations by trusted local 
health workers to fully inform them of the options and 
then offered a choice. Those that opt for prophylaxis dur-
ing peak transmission months could then be provided 
on-site supervised consumption of malaria prophylac-
tic drugs to improve compliance. However, this means a 
daily or weekly regimen over a period of two or 3 months 
and again raises the same concerns within medical prac-
titioners about the practicality of adequate compliance 
among workers who work shifts, take vacation or have 
days off, and sometimes even hide medication to hand to 
family members; poor compliance is a serious challenge 
that fosters development of drug resistance, a major 
global concern in the face of limited anti-malarial drug 
choices [10, 11].
If the primary objective of malaria chemoprophy-
laxis in local workers is to reduce the incidence of clini-
cal episodes by reducing parasite challenge in peak 
transmission season and yet not unduly affecting NAI, 
then a more practical option is to implement IPT. This 
means administering a full therapeutic parasite clearance 
dose once or twice during the high transmission season 
to fully-informed, signed-consent local workers. The 
practice of malarial IPT is well-established and widely-
applied among pregnant women and children [12–18] 
without rebound effect [14, 19] or negative impact on 
NAI [19]. The use of IPT will reduce parasite challenge 
within locally-recruited employees, diminish the likeli-
hood of breakthrough into clinical disease and, there-
fore, reduce the number of malaria cases, without undue 
Table 1 Geographic distribution of companies interviewed and key question responses




Do you offer or  
recommend malaria  
prophylactics to  
expatriate staff?
Do you offer or  
recommend malaria  
prophylactics to locally-
employed workers?
Do you engage in  
significant malaria control  
activities in surrounding  
communities?
Company A Chad Yes Yes No Yes
Company B Democratic Republic  
of the Congo
Yes Yes No Yes
Company A Ghana Yes Yes No Yes
Company A Guinea Yes Yes No Yes
Company C Mali Yes Yes No Yes
Company D Mozambique Yes Yes No No
Company E Tanzania Yes Yes No Yes
Company F Zambia Yes Yes No Yes
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impact on NAI status. This will reduce loss of production 
time in companies and improve general well-being of 
local employees.
However, implementation of either of the two prophy-
lactic options presented above—daily or weekly anti-
malarials during peak transmission months or occasional 
IPT—will present the challenge “So which drug should 
we use?”. The historical preferred choice of chloroquine 
and pyrimethamine is no longer available due to near 
universal parasite resistance to these drugs, and even the 
current choice of sulfadoxine–pyrimethamine for IPT is 
rapidly approaching the end of its practical usefulness 
because of widespread resistance [18]. One possibility 
for IPT would be the combination of artemether–lume-
fantrine, but the efficacy of this drug combination in IPT 
remains untested. Yet again, a clear and unambiguous 
policy option for large contractors appears elusive.
Parasite reduction and lowered incidence of clinical 
malaria in local inhabitants of malaria high-transmission 
areas can nevertheless be achieved in other ways, with-
out necessarily adversely impacting on NAI (Table  2). 
Many companies already engage in IRS and provision of 
bednets in local communities from which workers are 
recruited. This achieves a similar objective of reduced 
parasite transmission, but has wider impact and benefit 
at community level. Until greater clarity emerges regard-
ing appropriate choices of malaria prophylactic drugs 
for IPT in high transmission settings, probably the best 
intervention for worker well-being and company ben-
efit would be for large contractors to engage in malaria 
control activities that bring immediate and sustainable 
reduction in transmission intensity, such as IRS and pro-
vision of LLIN’s, which also complement and strengthen 
national government objectives of malaria reduction at 
community level.
Conclusions
Taking all the above factors into consideration, it 
appears that medical practitioners at mining and simi-
lar companies in high-transmission African coun-
tries have considerable justification for not advocating 
malaria prophylactic drugs to locally-recruited staff as 
a general rule, although exceptions will exist such as 
immune-compromised persons with HIV/AIDS. Some 
proof that these mining and other large companies are 
not withholding malaria prophylactic medication as 
a mere cost-saving exercise is the near-universal prac-
tice of such companies to engage in other extensive and 
costly malaria control practices, in particular provision 
of insecticide-treated bednets and indoor spraying of 
residential quarters with mosquito-combatting insec-
ticides. Such vector control programmes that result in 
reduced parasite transmission fundamentally achieve 
the same desired objective for locally recruited work-
ers, that being to reduce parasite challenge during peak 
transmission season which in turn leads to reduced 
incidence of clinical malaria, but allows persistence of 
NAI. Nevertheless, the use of IPT as a more directly tar-
geted method for periodic controlled parasite reduction 
in local communities deserves serious consideration for 
improved community well-being, provided appropriate 
anti-malarial drugs are available.
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